Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Slides:



Advertisements
Similar presentations
Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.
Advertisements

My Treatment Approach to Rheumatoid Arthritis
Figure 1 Lymphocytes during the disease
Figure 1 Role of innate lymphoid cells (ILCs) in steady state,
of different experimental arthritis models
Figure 1 Historical evolution of the clinical classification and
Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Enthesitis versus synovitis
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Structure of TNF antagonists
Figure 1 Induction of immune tolerance
Figure 3 Methods to detect trough levels of therapeutic antibodies
Figure 2 Assays for detecting antidrug antibodies to TNF inhibitors
My Treatment Approach to Rheumatoid Arthritis
Figure 4 Simplified T cell and antigen presenting
Figure 3 Proposed mechanisms underlying the links
Figure 2 Heat map of targeted therapies in autoimmune diseases
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 Main functions of IL-1
Figure 4 Involvement of SEMA4D in the pathogenesis
Figure 2 Targeted versus untargeted metabolomics approaches
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
The Inflammasomes in Autoinflammatory Diseases with Skin Involvement
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 GlyR antibody binding
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases.
Figure 3 Transcriptome studies performed in the target
Figure 2 Shared genetic loci in systemic autoimmune diseases
Figure 7 Defects in apoptosis
Figure 1 Location of HLA variants known to be associated
Figure 3 Defects in the T cell receptor signalling pathway
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 Approaches to targeting inhibitory immune receptors
Figure 1 Pharmacodynamics of methotrexate in RA
Figure 1 Activation and signalling of IL-1
Figure 2 Overlap of associated loci among five rheumatic diseases
Figure 2 Interaction effects between heterozygous HLA‑DRB1
Nat. Rev. Rheumatol. doi: /nrrheum
Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.
Figure 3 Statistical approaches for the analysis of metabolomic data
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 3 Effect of sialylated glycoforms on IgG activity
Figure 3 Multi-hit model for autoimmune diseases
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Research advances in osteoarthritis management
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Reproductive health in patients with rheumatic diseases
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Patterns of joint and organ involvement in rheumatic disease
Figure 1 Extrinsic and intrinsic pathways of apoptosis
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 The role of macrophages in RA
Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.
Nat. Rev. Rheumatol. doi: /nrrheum
Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.
Anti-CarALB antibody prevalence and levels in RA and other CTD
Presentation transcript:

Figure 3 Strategies to achieve therapeutic inhibition of IL-1 Figure 3 | Strategies to achieve therapeutic inhibition of IL-1. Structural, pharmacological and disease characteristics of current interleukin IL-1 inhibitors. Rilonacept has one extracellular domain of IL-1 receptor type 1 (IL-1R1) and one of IL-1 receptor accessory protein (IL-1RAcP) bound to the Fc portion of IgG. AOSD, adult onset Still disease; CAPS, cryopyrin-associated periodic syndrome; CPPD, calcium pyrophosphate disease; CP, calcifying periarthritis; CVD, cardiovascular disease; IL-1Ra, IL-1 receptor antagonist; mAb, monoclonal antibody; RA, rheumatoid arthritis; sJIA, systemic juvenile idiopathic arthritis. Schett, G. et al. (2015) Interleukin‑1 function and role in rheumatic disease Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.166